Emergent BioSolutions (EBS) EBT (2011 - 2026)

Emergent BioSolutions' EBT history runs 16 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• On a quarterly basis, EBT fell 85.54% year-over-year to $13.4 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 105.62% increase from a year earlier, with the FY2025 full-year figure at $82.8 million, up 157.94% from the prior year.
• EBT advanced to $13.4 million in Q1 2026 per EBS's latest filing, from -$50.7 million in the prior quarter.
• Across five years, EBT topped out at $142.4 million in Q3 2024 and bottomed at -$269.8 million in Q2 2024.
• The 5-year median for EBT is -$50.7 million (2025), against an average of -$58.4 million.
• Across the five-year window, EBT tumbled 4126.32% in 2023 and jumped 666.12% in 2025, its largest moves.
• Year by year, EBT stood at -$61.4 million in 2022, then advanced by 11.24% to -$54.5 million in 2023, then surged by 49.36% to -$27.6 million in 2024, then sank by 83.7% to -$50.7 million in 2025, then soared by 126.43% to $13.4 million in 2026.
• Per Business Quant, the three latest EBS EBT figures stand at $13.4 million (Q1 2026), -$50.7 million (Q4 2025), and $57.6 million (Q3 2025).